Global Calcium Channel Blocker Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Calcium Channel Blocker Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Calcium channel blockers（CCBs） are medications which are used control high blood pressure, chest pain and arrhythmia. They are available through prescription and work by relaxing blood vessels and increase the blood and oxygen supply to the heart. This reduces the workload of the heart. It can be prescribed by itself or in combination with other medications to treat high blood pressure and angina. There are a few different types of CCB and each works in a slightly different way.
Calcium Channel Blocker report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Calcium Channel Blocker market is projected to reach US$ 86 million in 2034, increasing from US$ 77 million in 2022, with the CAGR of 1.6% during the period of 2024 to 2034. Demand from Hypertension and Coronary Artery Disease are the major drivers for the industry.
Global Calcium Channel Blocker key players include Pfizer, Aventis, Searle, Bayer, AstraZeneca, etc.
North America is the largest market, with a share about 30%, followed by Europe, and China, both have a share about 40 percent.
In terms of product, Amlodipine is the largest segment, with a share over 55%. And in terms of application, the largest application is Hypertension, followed by CHD, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Calcium Channel Blocker market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Pfizer
Aventis
Searle
Bayer
AstraZeneca
Knoll Pharmaceuticals
Wyeth-Ayerst
AstraZeneca
Novartis
Sanofi
Segment by Type
Dihydropyridine
Diltiazem
Verapamil
Others
Hypertension
Coronary Artery Disease
Arrhythmia
Cardiomyopathy
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Calcium Channel Blocker market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Calcium Channel Blocker, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Calcium Channel Blocker industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Calcium Channel Blocker in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Calcium Channel Blocker introduction, etc. Calcium Channel Blocker Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Calcium Channel Blocker market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Calcium Channel Blocker report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Calcium Channel Blocker market is projected to reach US$ 86 million in 2034, increasing from US$ 77 million in 2022, with the CAGR of 1.6% during the period of 2024 to 2034. Demand from Hypertension and Coronary Artery Disease are the major drivers for the industry.
Global Calcium Channel Blocker key players include Pfizer, Aventis, Searle, Bayer, AstraZeneca, etc.
North America is the largest market, with a share about 30%, followed by Europe, and China, both have a share about 40 percent.
In terms of product, Amlodipine is the largest segment, with a share over 55%. And in terms of application, the largest application is Hypertension, followed by CHD, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Calcium Channel Blocker market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Pfizer
Aventis
Searle
Bayer
AstraZeneca
Knoll Pharmaceuticals
Wyeth-Ayerst
AstraZeneca
Novartis
Sanofi
Segment by Type
Dihydropyridine
Diltiazem
Verapamil
Others
Segment by Application
Hypertension
Coronary Artery Disease
Arrhythmia
Cardiomyopathy
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Calcium Channel Blocker market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Calcium Channel Blocker, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Calcium Channel Blocker industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Calcium Channel Blocker in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Calcium Channel Blocker introduction, etc. Calcium Channel Blocker Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Calcium Channel Blocker market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices